Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables (2020 - 2024)

Historic Receivables for Janux Therapeutics (JANX) over the last 5 years, with Q2 2024 value amounting to $12.1 million.

  • Janux Therapeutics' Receivables changed N/A to $12.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $12.1 million, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2023, which is N/A changed from last year.
  • Per Janux Therapeutics' latest filing, its Receivables stood at $12.1 million for Q2 2024.
  • Janux Therapeutics' Receivables' 5-year high stood at $12.1 million during Q2 2024, with a 5-year trough of $400000.0 in Q2 2021.
  • Over the past 5 years, Janux Therapeutics' median Receivables value was $2.2 million (recorded in 2023), while the average stood at $4.0 million.
  • Over the last 5 years, Janux Therapeutics' Receivables had its largest YoY gain of 45062.5% in 2024, and its largest YoY loss of 45062.5% in 2024.
  • Janux Therapeutics' Receivables (Quarter) stood at $8.0 million in 2020, then plummeted by 95.0% to $400000.0 in 2021, then rose by 25.0% to $500000.0 in 2022, then surged by 332.2% to $2.2 million in 2023, then surged by 457.89% to $12.1 million in 2024.
  • Its last three reported values are $12.1 million in Q2 2024, $4.4 million for Q1 2024, and $2.2 million during Q4 2023.